ORBIMED ADVISORS LLC 4
4 · Sionna Therapeutics, Inc. · Filed Feb 4, 2026
Research Summary
AI-generated summary of this filing
Sionna Therapeutics (SION) Director OrbiMed Advisors Sells Shares
What Happened
OrbiMed Advisors LLC, reported as a director of Sionna Therapeutics (SION), disposed of a total of 30,953 shares in two sale transactions on Feb 2–3, 2026. The first sale was 1,890 shares at $44.57 each ($84,237) on Feb 2; the second was 29,063 shares at $44.58 each ($1,295,629). Combined proceeds were approximately $1,379,866. These were sales (not purchases), so they represent liquidity-taking rather than a direct bullish signal.
Key Details
- Transaction dates and prices:
- 2026-02-02: Sold 1,890 shares @ $44.57 = $84,237
- 2026-02-03: Sold 29,063 shares @ $44.58 = $1,295,629
- Total shares sold: 30,953; total proceeds ≈ $1,379,866.
- Shares owned after transaction: Not specified in the information provided in this summary/filing excerpt.
- Footnotes of note:
- F1: The shares are held of record by OrbiMed Private Investments VIII, LP (OPI VIII). OrbiMed Advisors is the managing member of the GP and may be deemed to have voting/investment power; individual committee members disclaim beneficial ownership.
- F2: This Form 4 is jointly filed by OrbiMed Advisors and the related GP. They disclaim beneficial ownership except to the extent of any pecuniary interest; Peter A. Thompson (OrbiMed) serves as the fund’s designated director on Sionna’s board.
- Filing timeliness: Form 4 was filed on 2026-02-04 for transactions on 2026-02-02 and 02-03 — filed within the standard Section 16 reporting window (timely).
Context
These were institutional/director sales reported by a fund-affiliated reporting person (not an individual executive). Sales by insiders or affiliated funds can be routine (liquidity, portfolio rebalancing, fund-level decisions) and do not, by themselves, indicate company performance or management outlook.
Insider Transaction Report
- Sale
Common Stock
[F1][F2]2026-02-02$44.57/sh−1,890$84,237→ 3,559,765 total(indirect: See footnotes) - Sale
Common Stock
[F1][F2]2026-02-03$44.58/sh−29,063$1,295,629→ 3,530,702 total(indirect: See footnotes)
Footnotes (2)
- [F1]These securities are held of record by OrbiMed Private Investments VIII, LP ("OPI VIII"). OrbiMed Capital GP VIII LLC ("GP VIII") is the general partner of OPI VIII and OrbiMed Advisors LLC ("OrbiMed Advisors") is the managing member of GP VIII. By virtue of such relationships, GP VIII and OrbiMed Advisors may be deemed to have voting and investment power with respect to the shares held by OPI VIII and as a result may be deemed to have beneficial ownership of such shares. OrbiMed Advisors exercises investment and voting power through a management committee comprised of Carl L. Gordon, Sven H. Borho, and W. Carter Neild, each of whom disclaims beneficial ownership of the shares held by OPI VIII.
- [F2]This report on Form 4 is jointly filed by OrbiMed Advisors and GP VIII. Each of the Reporting Persons disclaims beneficial ownership of the securities reported herein for purposes of Rule 16a-1(a) under the Securities Exchange Act of 1934, as amended (the "Exchange Act"), except to the extent of its pecuniary interest therein, if any. The Reporting Persons have designated a representative, Peter A. Thompson, a member of OrbiMed Advisors, to serve on the Issuer's board of directors. This report shall not be deemed an admission that any such entity or person is a beneficial owner of such securities for purposes of Section 16 of the Exchange Act, or for any other purpose.